ECN Capital Reports US ($0.05) in Adjusted Net (Loss) per Common Share in Q4-2023

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

TORONTO, March 21, 2024 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or the “Company”) today reported financial results for the three-month period and year ended December 31, 2023. For the three-month period ended December 31, 2023, ECN Capital reported Adjusted net (loss) applicable to common shareholders from continuing operations of ($13.5) million or ($0.05) per share (basic) versus $0.5 million or $0.00 per share (basic) for the previous three-month period and $4.1 million or $0.02 per share (basic) for the same period last year. “While 2023 was a difficult year, ECN and its businesses have resumed a growth trajectory in 2024”, said Steven Hudson, CEO of ECN Capital Corp. “We have substantially resolved the challenges that affected performance last year and successfully transitioned management with new leadership...

Diversified Royalty Corp. Announces Record Fourth Quarter Adjusted Revenue(1) and Record Year End 2023 Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months (“Q4 2023”) and year ended December 31, 2023. Highlights The weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 6.8% in Q4 2023 and 8.4% for the year ended December 31, 2023, compared to 8.6% in Q4 2022 and 11.6% for the year ended December 31, 2022. Revenue was $16.4 million in Q4 2023 and $56.5 million for the year ended December 31, 2023, up 28.9% and 25.0%, respectively, compared to $12.7 million in Q4 2022 and $45.2 million for the year ended December 31, 2022. Adjusted revenue1 of $17.7 million in Q4 2023 and $61.6 million for the year ended December 31, 2023, up 26.4% and 22.7%, respectively,...

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone’s novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights. “2023 marked a transformative...

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Written by Customer Service on March 21, 2024. Posted in Public Companies.

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024. A live webcast of the fireside chat will be available on the Events & News – Presentations page of Jasper’s Investor Relations website. An archived replay of the fireside chat will be available on Jasper’s website for 30 days following the live broadcast. About JasperJasper is a clinical-stage...

UpHealth Provides Corporate Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

~ Glocal Ruling from Arbitral Tribunal in Favor of Company for up to $110.2 Million in Damages ~ ~ Sale of Cloudbreak Health Business Closed on March 15, 2024 ~ ~ Gross Cash Proceeds of $180 Million from the Cloudbreak Sale Will Be Used to Pay Down Debt, Including All of the Company’s $115 Million 2026 Notes and a Substantial Portion of its $57.2 Million 2025 Notes ~ ~ Continues Simplification Strategy Focused on Profitable TTC Behavioral Healthcare Business ~ DELRAY BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) — UpHealth, Inc. (“we,” “UpHealth,” or the “Company”) (OTC: UPHL) today provided a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2023. “In short, 2023 was a challenging, yet transformative, year for UpHealth, as we continued to take steps to stabilize the business,”...

DBM Global’s Banker Steel Tops Out JFK’s New Terminal One Headhouse

Written by Customer Service on March 21, 2024. Posted in Public Companies.

JFK’s New Terminal One Headhouse Topping Out DBM Global Inc. celebrates a monumental milestone of its subsidiaries Banker Steel Co. LLC and NYC Constructors LLC in placing the final piece of major structural steel on top of JFK International Airport’s New Terminal One Headhouse. PHOENIX, March 21, 2024 (GLOBE NEWSWIRE) — DBM Global Inc. (“DBM Global”) marked another construction achievement as its subsidiary Banker Steel Co. LLC (“Banker Steel”) placed the final piece of major structural steel on top of JFK International Airport’s New Terminal One Headhouse on Tuesday, March 19th. The ceremonial piece lifted in place is one of the highest points of the entire terminal that will encompass 2.4 million square feet as the largest airport terminal in the United States. DBM Global CEO & Chairman Rustin Roach commented, “Banker...

Brookfield Corporation Announces Results of Conversion of its Series 34 Preferred Shares

Written by Customer Service on March 21, 2024. Posted in Public Companies.

BROOKFIELD, NEWS, March 21, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for the conversion of its Cumulative Class A Preference Shares, Series 34 (the “Series 34 Shares”) (TSX: BN.PF.B) into Cumulative Class A Preference Shares, Series 35 (the “Series 35 Shares”), there were 257,216 Series 34 Shares tendered for conversion, which is less than the one million shares required to give effect to conversion into Series 35 Shares. Accordingly, there will be no conversion of Series 34 Shares into Series 35 Shares and holders of Series 34 Shares will retain their Series 34 Shares. About Brookfield Corporation Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions...

AGF Investments Announces Closure and Liquidation of AGF Global Infrastructure ETF, AGF Global Sustainable Equity Fund and AGF Emerging Markets Equity Fund

Written by Customer Service on March 21, 2024. Posted in Public Companies.

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) — AGF Investments* (TSX:AGF.B) announced today the closure and liquidation of AGF Global Infrastructure ETF (GLIF), AGF Global Sustainable Equity Fund and AGF Emerging Markets Equity Fund (collectively “the Funds”) on or about April 30, 2024 (the “Liquidation Date”). The decision to close and liquidate the Funds was driven by the firm’s continued effort to simplify and streamline its offerings; as well as the small number of Fund investors, relatively low Fund assets and the costs associated with maintaining the Funds. AGF Global Infrastructure ETF (GLIF or the “ETF”) Liquidation The last day of trading on NYSE Arca, Inc. (“NYSE Arca”) for AGF Global Infrastructure ETF is expected to be April 12, 2024. Effective upon the close of business on April 12, 2024, the ETF will no longer accept...

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

Written by Customer Service on March 21, 2024. Posted in Public Companies.

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer. “Working closely with Dave has been an absolute privilege,” said Matt D’Onofrio, incoming Chief Executive Officer of Evoke Pharma. “His relentless leadership resulted in our company developing and launching a highly unique and impactful therapy for patients suffering from diabetic gastroparesis. As CEO, I am driven by the same commitment to our...

FTAI Aviation Ltd. Announces 2023 PFIC Annual Information Statement

Written by Customer Service on March 21, 2024. Posted in Public Companies.

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) — FTAI Aviation Ltd. (“NASDAQ: FTAI”) is considered a Passive Foreign Investment Company (“PFIC”) for the taxable year ended on December 31, 2023. If a U.S. Holder owns a PFIC, the U.S. Holder may be required to file a Form 8621. U.S. Holders should consider making a Qualified Electing Fund (“QEF”) election with respect to FTAI. FTAI will post a 2023 “PFIC Annual Information Statement” to its website at https://ir.ftaiaviation.com/tax-information. This information is necessary for U.S. Holders that wish to make a QEF election. Investors are urged to consult their tax advisors regarding implications of owning a PFIC. About FTAI Aviation Ltd. FTAI owns and maintains commercial jet engines with a focus on CFM56 and V2500 engines. FTAI’s propriety portfolio of products, including The Module...

Day: March 21, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice